PRESS RELEASE published on 05/19/2025 at 14:01, 1 year 2 months ago Tharimmune Appoints Renowned Counter-Terrorism and Critical Infrastructure Expert James Gordon Liddy (CDR US Navy SEAL (Ret)) as Key Strategic Advisor Against Weaponized Fentanyl and Other High-Potency Opioids Following Positive FDA Feedback Tharimmune, Inc. appoints James Gordon Liddy as strategic advisor for TH104 development, targeting high-potency opioid exposure. FDA feedback positive for prophylaxis indication Tharimmune Inc. FDA Feedback High-Potency Opioids James Gordon Liddy TH104 Development
BRIEF published on 05/06/2025 at 14:06, 1 year 3 months ago Tharimmune Reports Positive Phase 1 Results for TH104 Tharimmune Inc. FDA Feedback Phase 1 Study Opioid Prophylaxis TH104 Buccal Film
BRIEF published on 05/06/2025 at 14:06, 1 year 3 months ago Tharimmune annonce des résultats positifs de phase 1 pour le TH104 Tharimmune Inc. Étude De Phase 1 Commentaires De La FDA Prophylaxie Aux Opioïdes Film Buccal TH104
PRESS RELEASE published on 05/06/2025 at 14:01, 1 year 3 months ago Tharimmune Presents Positive Clinical Data Highlighting TH104 Metabolic Profile and Advances Program for Prophylaxis Against Ultrapotent Opioid Exposure Following FDA Feedback Tharimmune, Inc. presents promising pharmacokinetic and metabolism data of TH104, a buccal film of nalmefene, for prophylaxis against opioid exposure. Study results showcased at Digestive Disease Week 2025 Tharimmune Inc. TH104 Buccal Film Pharmacokinetic Study Opioid Prophylaxis
BRIEF published on 05/01/2025 at 14:06, 1 year 3 months ago Le TH104 de Tharimmune sera présenté lors de conférences médicales importantes Biopharmaceutique TH104 Tharimmune DDW 2025 EASL 2025
BRIEF published on 05/01/2025 at 14:06, 1 year 3 months ago Tharimmune's TH104 to Be Presented at Notable Medical Conferences TH104 Biopharmaceutical Tharimmune DDW 2025 EASL 2025
PRESS RELEASE published on 05/01/2025 at 14:01, 1 year 3 months ago Tharimmune Abstracts Accepted for Presentation at Upcoming DDW and EASL Conferences Tharimmune, Inc. announces presentation of clinical data on lead drug TH104 at DDW and EASL Annual Meetings in May 2025, addressing unmet medical needs in immunology & inflammation Tharimmune Inc. TH104 Clinical Data Immunology Unmet Medical Needs
BRIEF published on 04/30/2025 at 14:06, 1 year 3 months ago Tharimmune élargit son conseil d'administration avec de nouvelles nominations Stratégie De Croissance Biopharmaceutique Direction Nominations Au Conseil D'administration Tharimmune
BRIEF published on 04/30/2025 at 14:06, 1 year 3 months ago Tharimmune Expands Board with New Appointments Growth Strategy Biopharmaceutical Leadership Board Appointments Tharimmune
PRESS RELEASE published on 04/30/2025 at 14:01, 1 year 3 months ago Tharimmune Appoints Clay Kahler and Gary Stetz to its Board of Directors Tharimmune, Inc. appoints Clay Kahler and Gary Stetz to its Board of Directors, expanding to 9 members. Kahler brings life sciences expertise while Stetz contributes financial acumen Board Of Directors Financial Expertise Tharimmune Clay Kahler Gary Stetz
Published on 08/14/2026 at 20:05, 21 minutes ago GeoVolt Power Corp. and Orovada Lithium Project Update
Published on 08/14/2026 at 16:55, 3 hours 31 minutes ago SLAM Reports 1.19% Copper Equivalent Over 24.6 Metres in Hole GW26-29 From the Goodwin Copper-Nickel-Cobalt Project
Published on 08/14/2026 at 13:30, 6 hours 56 minutes ago Digi Power X Reports Second Quarter 2026 Financial Results and Provides Operational Update and 2027 Outlook
Published on 08/14/2026 at 13:15, 7 hours 11 minutes ago Mako Mining Reports Q2 2026 Financial Results, Including Adjusted EBITDA(1) of US$31.7 Million and EPS of US$0.16/Share
Published on 08/14/2026 at 13:10, 7 hours 16 minutes ago SouthGobi Announces Second Quarter 2026 Unaudited Financial and Operating Results
Published on 08/14/2026 at 18:15, 2 hours 11 minutes ago Fuller, Smith & Turner PLC: Transaction in own shares
Published on 08/14/2026 at 16:05, 4 hours 21 minutes ago GATORADE WELCOMES AITANA BONMATÍ TO TEAM GATORADE AHEAD OF THE NEW FOOTBALL SEASON
Published on 08/13/2026 at 18:00, 1 day 2 hours ago Chiffre d’affaires du 1er trimestre 2026-27 : 14,4 M€
Published on 08/11/2026 at 17:45, 3 days 2 hours ago DAMARTEX / Droits de vote bruts et réels au 31 juillet 2026
Published on 08/11/2026 at 17:40, 3 days 2 hours ago Infotel : Déclaration des transactions sur actions propres réalisées du 3 au 7 août 2026 dans le cadre du programme de rachat d’actions
Published on 08/10/2026 at 18:00, 4 days 2 hours ago AXA: Information relating to the number of voting rights and shares making up the share capital on 31/07/2026
Published on 08/10/2026 at 18:00, 4 days 2 hours ago AXA : Information relative au nombre total de droits de vote et d'actions composant le capital social au 31/07/2026